CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Sam Whiting, M.D., Ph.D.
Calithera Biosciences, Inc
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
133 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Southern Highlands Private Hospital (cancer Centre)
Bowral, New South Wales, Australia
- Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia
- Macquarie University Hospital
North Ryde, New South Wales, Australia
- Liverpool Hospital
Sydney, New South Wales, Australia
- Tweed Hospital
Tweed Heads, New South Wales, Australia
- Pindara Private Hospital
Benowa, Queensland, Australia
- Cairns Hospital
Cairns, Queensland, Australia
- Mater Misericordiae Limited - Division of Cancer Services
South Brisbane, Queensland, Australia
- Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
- Ballarat Health Services
Ballarat, Victoria, Australia
- Peninsula Private Hospital
Frankston, Victoria, Australia
- Cabrini Hospital
Malvern, Victoria, Australia
- Goulburn Valley Health
Shepparton, Victoria, Australia
- Hollywood Private Hospital
Nedlands, Western Australia, Australia
- Centre Hospitalier Régional Universitaire (chru) de Besançon - Jean-Minjoz
Besançon, France
- Chu de Bordeaux Hôpital Saint André
Bordeaux, France
- Centre François Baclesse
Caen, France
- Centre Jean Perrin
Clermont-Ferrand, France
- Centre Hospitalier Universitaire (chu) Henri-Mondor
Créteil, France
- Centre Georges-François Leclerc
Dijon, France
- Centre Léon Bérard
Lyon, France
- Institut Paoli-Calmettes Service D'Urologie
Marseille, France
- Institut de Cancérologie de Montpellier (icm)
Montpellier, France
- Centre Antoine Lacassagne
Nice, France
- Hôpital Européen Georges-Pompidou (hegp)
Paris, France
- Institut de Cancérologie de L'Ouest (ico) - Centre René Gauducheau
Saint-Herblain, France
- Chu de Strasbourg (les Hôpitaux Universitaires de Strasbourg)
Strasbourg, France
- Iucto Bureau Des Essais Cliniques (institut Claudius Regaud)
Toulouse, France
- Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, France
- Institut Gustave Roussy - Le Département de Medecine Oncologique
Villejuif, France
- Medical University Heidelberg, Nct (national Center for Tumour Diseases), Medical Oncology
Heidelberg, Baden-Wurttemberg, Germany
- Technischen Universitat München - Urologische Klinik
München, Bavaria, Germany
- Charité Universitätsmedizin Berlin, Dept. of Interdisciplinary Urology
Berlin, Germany
- Universitätsklinikum Carl Gustav Carus An Der Technischen Universität Dresden, Klinik Und Poliklinik
Dresden, Germany
- Universitätsklinikum Essen (aör) Westdeutsches Tumorzentrum
Essen, Germany
- Medizinische Hochschule Hannover
Hanover, Germany
- Universitätsklinikum Tübingen, Klinik Für Urologie
Tübingen, Germany
- Presidio Ospedaliero Antonio Perrino - U.O.C. Oncologia Medica
Brindisi, Italy
- S.C. Oncologia - Asst Cremona P.O. Ospedale Di Cremona
Cremona, Italy
- Fondazione Irccs Istituto Nazionale Dei Tumori
Milan, Italy
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 24 Apr 2018
- Primary completion
- 31 Aug 2020
- Completion
- 16 Jul 2021
- Last update posted
- 20 Mar 2023
- Registered enrollment
- 444
- Registry id
- NCT03428217
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.